RESEARCHER PROFILE

Jutta Petschenka

← Back to Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

J

Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyVirus-based gene therapy researchCAR-T cell therapy research

Jutta Petschenka works in Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, T-cell and B-cell Immunology, Virus-based gene therapy research, CAR-T cell therapy research. Recorded institutional associations include University Medical Center of the Johannes Gutenberg University Mainz, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz.

21Publications
771Citations
8H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis

    2021 · 515 citations
  2. CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity

    2022 · 121 citations
  3. CD4+ T cells license Kupffer cells to reverse CD8+ T cell dysfunction induced by hepatocellular priming

    2025 · 36 citations
  4. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer

    2021 · 25 citations
  5. Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

    2019 · 22 citations
  6. Detection of Mycobacterium avium ssp. paratuberculosis in ileocaecal lymph nodes collected from elderly slaughter cows using a semi-nested IS900 polymerase chain reaction

    2011 · 18 citations
  7. FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines

    2016 · 16 citations
  8. A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo

    2018 · 16 citations
  9. Unexpected high frequency of neurofibroma in the celiac ganglion of German cattle

    2020 · 5 citations
  10. CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

    2015 · 1 citations
  11. Gene Therapy With a High-Affinity Single-Chain p53-Specific TCR Mediates Potent Anti-Tumor Response Without Inducing Gvhd In Vivo

    2013 · 0 citations
  12. CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2016, Mainz, Germany

    2016 · 0 citations
  13. Abstract 3741: Antimetastatic activity of ISTH0047, a potent and selective TGF-beta 2 antisense oligonucleotide, in syngeneic lung metastatic model of mouse 4T1 mammary carcinoma

    2016 · 0 citations
  14. Safe and Effective Adoptive T-Cell Receptor Transfer with a High Affinity Single Chain p53(264–272)-Specific TCR

    2012 · 0 citations
  15. Correction to: Unexpected high frequency of neurofibroma in the celiac ganglion of German cattle

    2020 · 0 citations
  16. 2284P Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)

    2023 · 0 citations
  17. Abstract 6658: TcE armed oncolytic virus VSV-GP combines oncolysis and T-cell retargeting for improved efficacy

    2024 · 0 citations
  18. OS-026 CD4+T cells license Kupffer cells to produce IL-27 and reverse the CD8+T cell dysfunction induced by hepatocellular priming

    2025 · 0 citations
  19. Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response

    2026 · 0 citations

← Return to the university profile